CN115135313A - 治疗前列腺癌的方法 - Google Patents

治疗前列腺癌的方法 Download PDF

Info

Publication number
CN115135313A
CN115135313A CN202080080511.2A CN202080080511A CN115135313A CN 115135313 A CN115135313 A CN 115135313A CN 202080080511 A CN202080080511 A CN 202080080511A CN 115135313 A CN115135313 A CN 115135313A
Authority
CN
China
Prior art keywords
compound
formula
day
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080080511.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·P·克鲁
R·J·哈斯克尔三世
M·D·摩尔
L·B·斯奈德
J·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avenas Enterprises
Original Assignee
Avenas Enterprises
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avenas Enterprises filed Critical Avenas Enterprises
Publication of CN115135313A publication Critical patent/CN115135313A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080080511.2A 2019-10-22 2020-10-21 治疗前列腺癌的方法 Pending CN115135313A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962924655P 2019-10-22 2019-10-22
US62/924,655 2019-10-22
US201962945418P 2019-12-09 2019-12-09
US62/945,418 2019-12-09
US202063028843P 2020-05-22 2020-05-22
US63/028,843 2020-05-22
US202063032453P 2020-05-29 2020-05-29
US63/032,453 2020-05-29
PCT/US2020/056684 WO2021081108A1 (en) 2019-10-22 2020-10-21 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
CN115135313A true CN115135313A (zh) 2022-09-30

Family

ID=73449188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080511.2A Pending CN115135313A (zh) 2019-10-22 2020-10-21 治疗前列腺癌的方法

Country Status (10)

Country Link
US (2) US20210113557A1 (https=)
EP (1) EP4048236A1 (https=)
JP (2) JP7716396B2 (https=)
KR (1) KR20220087482A (https=)
CN (1) CN115135313A (https=)
AU (1) AU2020370150A1 (https=)
CA (1) CA3158411A1 (https=)
IL (1) IL292359A (https=)
MX (1) MX2022004808A (https=)
WO (1) WO2021081108A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116783179A (zh) * 2020-10-21 2023-09-19 阿尔维纳斯运营股份有限公司 用于雄激素受体蛋白的靶向降解的化合物和方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
WO2022048605A1 (zh) * 2020-09-04 2022-03-10 南昌奥瑞药业有限公司 一种杂环化合物、其制备方法、中间体、组合物以及应用
JP2023552818A (ja) * 2020-12-11 2023-12-19 アルビナス・オペレーションズ・インコーポレイテッド 前立腺癌を治療する方法
CN113620931B (zh) * 2021-09-13 2023-06-09 中国海洋大学 一种雄激素受体抑制剂及其用途
US20250248999A1 (en) * 2022-04-21 2025-08-07 Arvinas Operations, Inc. Bavdegalutamide and combinations thereof for use in treating prostate cancer
WO2024233696A1 (en) * 2023-05-09 2024-11-14 Arvinas Operations, Inc. Bavdegalutamide for treating prostate cancer without ar l702h mutation
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
CN107249567A (zh) * 2014-11-21 2017-10-13 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
US20180099940A1 (en) * 2016-10-11 2018-04-12 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
CN109310664A (zh) * 2016-06-10 2019-02-05 田纳西大学研究基金会 选择性雄激素受体降解剂(sard)配体和其使用方法
JOP20190067A1 (ar) * 2016-09-30 2019-03-28 Janssen Pharmaceutica Nv طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
CN107249567A (zh) * 2014-11-21 2017-10-13 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
US20180099940A1 (en) * 2016-10-11 2018-04-12 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIALS.GOV: "Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)", pages 1 - 4, Retrieved from the Internet <URL:《https://classic.clinicaltrials.gov/ct2/show/NCT03888612》> *
TAAVI NEKLESA，等: "An oral androgen receptor PROTAC degrader for prostate cancer", 《2018 GU ASCO》 *
TAAVI NEKLESA，等: "ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer", 《JOURNAL OF CLINICAL ONCOLOGY》, vol. 37, no. 7 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116783179A (zh) * 2020-10-21 2023-09-19 阿尔维纳斯运营股份有限公司 用于雄激素受体蛋白的靶向降解的化合物和方法

Also Published As

Publication number Publication date
JP7716396B2 (ja) 2025-07-31
JP2022553954A (ja) 2022-12-27
US20230128132A1 (en) 2023-04-27
AU2020370150A1 (en) 2022-05-12
US20210113557A1 (en) 2021-04-22
JP2025157436A (ja) 2025-10-15
CA3158411A1 (en) 2021-04-29
WO2021081108A1 (en) 2021-04-29
EP4048236A1 (en) 2022-08-31
IL292359A (en) 2022-06-01
KR20220087482A (ko) 2022-06-24
MX2022004808A (es) 2022-06-08

Similar Documents

Publication Publication Date Title
CN115135313A (zh) 治疗前列腺癌的方法
US20240066032A1 (en) Methods of treating prostate cancer
CN114667147B (zh) 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
US20210353621A1 (en) Methods of treating prostate cancer
CN116744925A (zh) 用四氢萘衍生物作为雌激素受体降解剂治疗乳腺癌的方法
US20250248999A1 (en) Bavdegalutamide and combinations thereof for use in treating prostate cancer
CN101663026A (zh) 氨基甲酸苯基烷基酯组合物
CN120344248A (zh) 用于雄激素受体的靶向降解的化合物和方法
CN116761607A (zh) 治疗前列腺癌的方法
HK40119356A (zh) 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
JP2005263788A (ja) インドリン化合物を含有する安定化された医薬組成物
JP2007051085A (ja) インドリン化合物を含有する安定化された医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20260410

AD01 Patent right deemed abandoned